The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (I): ##STR00001##
wherein: R.sub.1 is H, —OMe, Me, or one or more electron withdrawing groups; R.sub.2 and R.sub.3 are each independently H or alkyl or, taken together, form a 4- to 8-membered heterocyclic ring with the adjacent nitrogen atom; R.sub.4 is H or alkyl; R.sub.5 is H or one or more electron donating groups; and n is 1 to 4.

A composition has effects for promoting endoplasmic reticulum (ER)-phagy, a composition for maintaining ER homeostasis or reducing ER stress, and a pharmaceutical composition for preventing and/or treating ER-stress-related diseases. The composition contains a p62 ligand compound as an active ingredient. The p62 ligand compound can modulate p62 to interact with a receptor associated with autophagic degradation of ER component, modulate oligomerization and/or aggregation of the receptor, modulate formation of autophagosomes, and the like. Thus, uses of p62 ligand compound in inducing ER-autophagy are provided.

The present description relates to 1-piperidinepropionic acid or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising it, for use in the treatment of chronic fibrosing diseases.

The present description relates to 1-piperidinepropionic acid or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising it, for use in the treatment of chronic fibrosing diseases.

Compounds, and compositions, methods, and uses thereof, are described herein for treating brain injuries.

Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.

Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.